YBX1 and hepatocellular carcinoma: For example, in hepatocellular carcinoma cells, circRNA-SORE can mediate hepatocellular carcinoma resistance to sorafenib by stabilizing YBX1 (67), while N-6-methyladenosine-modified circRNA-SORE can also maintain hepatocellular carcinoma resistance to sorafenib by regulating β-catenin signalin (69).